Achieving regulatory approval is often seen as the defining milestone for entering a new market. In practice, however, it marks only the beginning of a far more complex journey. In highly regulated and operationally fragmented environments such as Brazil and broader Latin America, the absence of a structured execution strategy frequently leads to stalled adoption, even for clinically validated technologies. Market entry, in this context, is not a regulatory event — it is an orchestrated process that requires alignment across clinical, operational, and logistical dimensions.

ALS | COSTA

Strategic Perspectives on Oncology Innovation and Market Development